Humacyte (HUMA) Other Accumulated Expenses (2023 - 2025)

Humacyte (HUMA) posted quarterly Other Accumulated Expenses of $61000.0 for Q2 2025, up 1.67% quarter-over-quarter from $60000.0 in Q1 2025.

Humacyte (HUMA) Other Accumulated Expenses (2023 - 2025) Analysis & Trends

Humacyte (HUMA) has reported Other Accumulated Expenses for 2 consecutive years, with $61000.0 the latest figure, recorded in Q2 2025.

In Q2 2025, Other Accumulated Expenses changed N/A year-over-year to $61000.0; the TTM figure through Jun 2025 stood at $61000.0 (changed N/A YoY), while the FY2023 annual figure was $53000.0, changed N/A from the prior year.
Other Accumulated Expenses improved to $61000.0 in Q2 2025 per HUMA's latest filing, from $60000.0 in the prior quarter.
Across five years, Other Accumulated Expenses topped out at $61000.0 in Q2 2025 and bottomed at $53000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Humacyte	150.77 Mn	150.77 Mn	-825,000.00

Download Data